• menopause

    New Research from the CWMH: History of Depression and Anxiety Predict Lower Quality of Life in Midlife Women

    The National Comorbidity Survey estimates that by the time women reach midlife, approximately 23% have experienced at least one episode of major depression and 30% have been diagnosed with an anxiety disorder.  Depression and anxiety disorders are each associated with impaired functioning and lower quality of life (QOL).  There is also some data to suggest that, even after a depressive episode resolves, those with a history of a affective illness have a lower quality of life than those without histories of depression, with impairment in social and interpersonal functioning.

    Soy Supplements: No Effect on Cognition in Postmenopausal Women

    Soy-based products have long been touted as a treatment for menopausal symptoms.  However, many of the clinical studies measuring the effectiveness of dietary sources of soy isoflavones (e.g., soy beverages, soy powder) for the treatment of menopausal vasomotor symptoms (i.e., hot flushes, night sweats) have been negative.  Less is known about the effects of soy on cognition.  A large clinical trial suggests that soy may not have any positive effects on cognition in postmenopausal women.

    In Brief: Menopausal Symptoms Usually Go Untreated

    In this study, half of women aged 45 to 60 years reported experiencing menopausal symptoms. 69% of these women reported that their symptoms have negatively  affected their lives. Among the women who endorsed menopausal symptoms, 72% had not received any treatment for their symptoms and 77% reported that they had not discussed treatment options with their healthcare providers.

    A New Website to Help Educate Menopausal Women about Their Treatment Options

    Ever since 2002 when several large-scale studies called into question the safety of long-term hormone replacement therapy (HRT), there has been confusion and conflicting opinions regarding the management of menopausal symptoms. Initially there was a movement to avoid HRT altogether; now it is becoming clearer that certain women may safely use and benefit from hormonal interventions.

    New Research from the CWMH: Progestins Do Not Negatively Affect Mood in Peri- and Postmenopausal Women

    More than half of all women initiating treatment with hormone therapy will stop within the first year of treatment, most often because of side effects.  Mood disturbance is a relatively common side effect that occurs with hormone therapy, and previous studies have suggested that progestins in the combined hormone preparations are responsible for these negative mood effects.

    Pomegranate Seed Oil for Hot Flashes?

    While phytoestrogens have gained attention as possible alternatives to hormone therapy for the treatment of menopausal symptoms, placebo-controlled studies have yielded mixed results.  Pomegranate seed oil is a very rich source of phytoestrogens.  In this prospective randomized, placebo-controlled, double-blinded trial, 81 postmenopausal women received two daily doses of either 30 mg pomegranate seed oil (PGS) or placebo.  The frequency of hot flashes decreased by 38.7% (P < 0.001) after 12 weeks of treatment with pomegranate seed oil and by 25.6% in the placebo group (P < 0.01). However, the difference between the two groups was not statistically significant (P = 0.17).   The authors suggest that it may take a longer period of observation to demonstrate a difference between pomegranate seed oil and placebo.

    Heavy Menstrual Bleeding More Common in Midlife Women with Histories of Depression

    Menstrual problems are common among premenopausal women and become more frequent with increasing reproductive age, especially just before and during perimenopause.  In the Study of Women's Health Across the Nation, a multisite study of menopause and aging, information regarding menstrual history was collected in a total of 934 premenopausal and early perimenopausal women between the ages of 42 and 52.  History of major depression was associated with an increased likelihood of heavy bleeding (odds ratio, 1.89), adjusting for recent major depression, menopause status, and other confounding factors. History of depression was not associated with other abnormal bleeding or premenstrual symptoms. Future longitudinal studies are needed to explore why past depression increases the likelihood of subsequent heavy menstrual bleeding in midlife women.  One possibility is that irregular fluctuations in estrogen levels may be responsible for both abnormal menstrual bleeding, as well as the dysregulation of neurotransmitter systems that mediate depressive symptoms.

    NAMS Supports the Use of Hormone Therapy in Perimenopausal and Recently Postmenopausal Women

    The North American Menopause Society (NAMS) has updated its 2010 recommendations regarding the use of postmenopausal hormone therapy (HT) based on evidence accumulated subsequent to the previous report.  In the decade since the first publication of the results from the Women's Health Initiative, we have accumulated evidence to indicate that multiple factors influence the effects of hormone therapy, including the type of estrogen used, the way the hormones are given, and the age and recency of menopause of the woman taking the medication. These factors also determine the risks associated with hormone therapy. 

    Go to Top